As of 2025-11-04, the Intrinsic Value of Eupraxia Pharmaceuticals Inc (EPRX.TO) is -2.86 CAD. This EPRX.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 8.00 CAD, the upside of Eupraxia Pharmaceuticals Inc is -135.77%.
Based on its market price of 8.00 CAD and our intrinsic valuation, Eupraxia Pharmaceuticals Inc (EPRX.TO) is overvalued by 135.77%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -2.86 - -2.86 | -2.86 | -135.77% |
| P/E | 8.01 - 8.01 | 8.01 | 0.1% |
| DDM - Stable | (4.39) - (10.70) | (7.55) | -194.3% |
| DDM - Multi | (0.38) - (0.71) | (0.49) | -106.1% |
| Market Cap (mil) | 404.80 |
| Beta | 0.84 |
| Outstanding shares (mil) | 50.60 |
| Enterprise Value (mil) | 385.03 |
| Market risk premium | 5.10% |
| Cost of Equity | 10.97% |
| Cost of Debt | 5.00% |
| WACC | 7.33% |